Gaucher disease-induced pluripotent stem cells display decreased erythroid potential and aberrant myelopoiesis

Stem Cells Translational Medicine

Volumn 4, Issue 8, 2015, Pages 878-886

  Sgambato, Judi A ^a   Park, Tea Soon ^b   Miller, Diana ^a   Panicker, Leelamma M ^a   Sidransky, Ellen ^c   Lun, Yu ^a   Awad, Ola ^a   Bentzen, Søren M ^a   Zambidis, Elias T ^b   Feldman, Ricardo A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Erythropoiesis; Hematopoiesis; Hematopoietic stem cells; Induced pluripotent stem cells; Monocyte; Myeloid cells; Stem progenitor cell

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; GLUCOSYLCERAMIDASE; LEUKOSIALIN;

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL MATURATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; GAUCHER DISEASE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MACROPHAGE; MYELOPOIESIS; PHENOTYPE; PLURIPOTENT STEM CELL; CELL LINEAGE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; PATHOLOGY; PHYSIOLOGY; TRANSPLANTATION;

CELL DIFFERENTIATION; CELL LINEAGE; GAUCHER DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MACROPHAGES; MYELOPOIESIS;

EID: 84937888128     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0213     Document Type: Article

References (49)

1. 1 Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010; 285:20423–20427.
2. 2 Rosenbloom BE, Weinreb NJ. Gaucher disease: A comprehensive review. Crit Rev Oncog 2013;18:163–175.
3. 3 Grabowski GA. Gaucher disease and other storage disorders. HematologyAmSoc Hematol Educ Program 2012;2012:13–18.
4. 4 Jmoudiak M, Futerman AH. Gaucher disease: Pathological mechanisms and modern management. Br J Haematol 2005;129:178–188.
5. 5 Zhao H, Grabowski GA. Gaucher disease: Perspectives on a prototype lysosomal disease. Cell Mol Life Sci 2002;59:694–707.
6. 6 Parkin JL, Brunning RD. Pathology of the Gaucher cell. Prog Clin Biol Res 1982;95:151–175.
7. 7 Boven LA, van Meurs M, Boot RG et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activatedmacrophages. AmJ Clin Pathol 2004;122: 359–369.
8. 8 Machaczka M, Klimkowska M, Regenthal S et al. Gaucher disease with foamy transformed macrophages and erythrophagocytic activity. J Inherit Metab Dis 2011;34:233–235.
9. 9 Bitton A, Etzell J, Grenert JP et al. Erythrophagocytosis in Gaucher cells. Arch Pathol Lab Med 2004;128:1191–1192.
10. 10 Panicker LM, Miller D, Park TS et al. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci USA 2012;109:18054–18059.
11. 11 Hughes D, Cappellini MD, Berger M et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007;138: 676–686.
12. 12 Thomas AS, Mehta A, Hughes DA. Gaucher disease: Haematological presentations and complications. Br J Haematol 2014;165: 427–440.
13. 13 Bratosin D, Tissier JP, Lapillonne H et al. A cytometric study of the red blood cells in Gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis. Cytometry B Clin Cytom 2011;80: 28–37.
14. 14 Franco M, Collec E, Connes P et al. Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease. Blood 2013;121:546–555.
15. 15 Adar T, Ben-Ami R, Elstein D et al. Aggregation of red blood cells in patients with Gaucher disease. Br J Haematol 2006;134: 432–437.
16. 16 Ayto R, Hughes DA. Gaucher disease and myeloma. Crit Rev Oncog 2013;18:247–268.
17. 17 Barak V, Acker M, Nisman B et al. Cytokines in Gaucher’s disease. Eur Cytokine Netw 1999;10:205–210.
18. 18 Panicker LM, Miller D, Awad O et al. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. STEM CELLS 2014;32:2338–2349.
19. 19 Takahashi K, Tanabe K, OhnukiM et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861–872.
20. 20 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–676.
21. 21 Cherry AB, Daley GQ. Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med 2013;64:277–290.
22. 22 Cherry AB, Daley GQ. Reprogramming cellular identity for regenerative medicine. Cell 2012;148:1110–1122.
23. 23 Azevedo JL, Feldman RA. Tinkering with transcription factors uncovers plasticity of somatic cells. Genes Cancer 2010;1:1089–1099.
24. 24 Goodridge HS. Induced pluripotent stem cell-derived myeloid phagocytes: Disease modeling and therapeutic applications. Drug Discov Today 2014;19:774–780.
25. 25 Tucker KL, Wang Y, Dausman J et al. A transgenic mouse strain expressing four drugselectable marker genes. Nucleic Acids Res 1997;25:3745–3746.
26. 26 Park TS, Zimmerlin L, Zambidis ET. Efficient and simultaneous generation of hematopoietic and vascular progenitors from human induced pluripotent stem cells. Cytometry A 2013;83:114–126.
27. 27 Zambidis ET, Park TS, Yu W et al. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008;112:3601–3614.
28. 28 Zhou HY, Yang XY, Tao LJ et al. Characterization of human embryonic stem cell-derived hematopoietic progenitor phenotype. In Vitro Cell Dev Biol Anim 2010;46:733–737.
29. 29 Vodyanik MA, Thomson JA, Slukvin II. Leukosialin (CD43) defines hematopoietic progenitors inhumanembryonic stem cell differentiation cultures. Blood 2006;108:2095–2105.
30. 30 Marsee DK, Pinkus GS, Yu H. CD71 (transferrin receptor): An effective marker for erythroid precursors in bone marrow biopsy specimens.AmJ Clin Pathol 2010;134:429–435.
31. 31 van den Akker E, Satchwell TJ, Pellegrin S et al. The majority of the in vitro erythroid expansion potential resides in CD34(2) cells, outweighing the contribution of CD34(+) cells and significantly increasing the erythroblast yield from peripheral blood samples. Haematologica 2010;95:1594–1598.
32. 32 Chen K, Liu J, Heck S et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc Natl Acad Sci USA 2009;106:17413–17418.
33. 33 Cox TM. Gaucher disease: Clinical profile and therapeutic developments. Biologics 2010; 4:299–313.
34. 34 Sidransky E, LaMarca ME, Ginns EI. Therapy for Gaucher disease: Don’t stop thinking about tomorrow. Mol Genet Metab 2007;90: 122–125.
35. 35 Berger J, Lecourt S, Vanneaux V et al. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br J Haematol 2010;150:93–101.
36. 36 Hughes DA, Pastores GM. The pathophysiology of GD—Current understanding and rationale for existing and emerging therapeutic approaches. Wien Med Wochenschr 2010;160: 594–599.
37. 37 Enquist IB, Nilsson E, Ooka A et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA 2006; 103:13819–13824.
38. 38 Mistry PK, Liu J, Yang M et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA 2010;107:19473–19478.
39. 39 Pavlova EV, Wang SZ, Archer J et al. B cell lymphoma and myeloma in murine Gaucher’s disease. J Pathol 2013;231:88–97.
40. 40 Orvisky E, Sidransky E, McKinney CE et al. Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr Res 2000;48:233–237.
41. 41 Eaves C, Lambie K. Atlas of HumanHematopoietic Colonies. Vancouver, BC, Canada: Stem Cell Technologies, 1995.
42. 42 Slukvin II. Hematopoietic specification from human pluripotent stem cells: Current advances and challenges toward de novo generation of hematopoietic stem cells. Blood 2013; 122:4035–4046.
43. 43 Chao MP, Seita J, Weissman IL. Establishment of a normal hematopoietic and leukemia stem cell hierarchy. Cold Spring Harb Symp Quant Biol 2008;73:439–449.
44. 44 Nakajima H. Role of transcription factors in differentiation and reprogramming of hematopoietic cells. Keio J Med 2011;60:47–55.
45. 45 Chotinantakul K, Leeanansaksiri W. Hematopoietic stem cell development, niches, and signaling pathways. Bone Marrow Res 2012;2012:270425.
46. 46 Brady RO. Enzyme replacement for lysosomal diseases. AnnuRevMed 2006;57:283–296.
47. 47 Hruska KS, LaMarca ME, Scott CR et al. Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008;29:567–583.
48. 48 Chen M, Wang J. Gaucher disease: Review of the literature. Arch Pathol Lab Med 2008;132:851–853.
49. 49 Koprivica V, Stone DL, Park JK et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000;66:1777–1786.